Back to Results
First PageMeta Content
Science / Pharmaceutical sciences / Food and Drug Administration / Design of experiments / Drug safety / Institutional review board / Clinical trial / Form FDA 483 / Clinical investigator / Pharmacology / Clinical research / Research


FDA Warning Letter to Agnesian Healthcare IRB[removed]
Add to Reading List

Document Date: 2013-04-05 08:46:05


Open Document

File Size: 146,16 KB

Share Result on Facebook

Company

Agnesian Healthcare IRB / /

Facility

National Cancer Institute / Research Food and Drug Administration Building / /

/

MedicalCondition

cancer / injury / Heart failure / Heart attack / High blood pressure / /

Organization

Scientific Investigations Office / National Cancer Institute / Institutional Review Board / Clinical Trial Support Unit / Food and Drug Administration / M.S. Acting Office Director Office / Cancer Trials Support Unit / Email FDA For Government For Press Combination Products Advisory Committees Science & Research Regulatory Information Safety Emergency Preparedness International Programs News / ICDs / Compliance Center for Drug Evaluation and Research Food and Drug Administration Building / Human Subject Protection Branch Office / Compliance Center for Drug Evaluation / Department of Health and Human Services / /

Person

N. Moreno / Little / Agnesian Healthcare / Silver Spring / Denise L. Burosh / James P. Mugan / Catherine Parker / /

/

Position

investigator / Chairman / President and Chief Executive Officer / Chairperson / clinical investigator / R.N. / /

ProvinceOrState

Wisconsin / Maryland / /

URL

http /

SocialTag